Number of women reporting adverse events ‐ not reported · women with urinary incontinence
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Disease‐specific quality of life · women with urinary incontinence
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
General health status evaluation e.g. Short Form (SF)‐36 ‐ not reported · women with urinary incontinence
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Number of women requiring further treatment such as surgery, drugs, mechanical devices (relapse) ‐ not reported · women with urinary incontinence
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Number of women cured · women with urinary incontinence
PFMT added to HSGS probably leads to higher number of women cured compared with HSGS alone (moderate certainty).
1 finding from 1 review
Number of women reporting incontinence at 1 year or more after treatment (subjective) ‐ not reported · women with urinary incontinence
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Objective measure of urine leakage (e.g. pad test) ‐ not reported · women with urinary incontinence
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
General health status evaluation e.g. Short Form (SF)‐36 ‐ not reported · women with urinary incontinence
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Number of women experiencing pain ‐ not reported · women with urinary incontinence
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Disease‐specific quality of life · women with urinary incontinence
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
General health status evaluation e.g. Short Form (SF)‐36 ‐ not reported · women with urinary incontinence
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Number of women requiring further treatment such as surgery, drugs, mechanical devices (relapse) ‐ not reported · women with urinary incontinence
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Number of women requiring further treatment such as surgery, drugs, mechanical devices (relapse) ‐ not reported · women with urinary incontinence
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Participants cured or improved · women with urinary incontinence
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Number of women reporting incontinence at 1 year or more after treatment (subjective) ‐ not reported · women with urinary incontinence
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adherence · HIV‐negative people at risk of TB infection1
It is very uncertain whether rifampicin plus pyrazinamide changes adherence compared with isoniazid (very low certainty).
1 finding from 1 review
Treatment‐limiting adverse events · HIV‐negative people at risk of TB infection1
Rifampicin plus pyrazinamide leads to higher treatment‐limiting adverse events compared with isoniazid (high certainty).
1 finding from 1 review
Hepatotoxicity · HIV‐negative people at risk of TB infection1
Rifampicin plus pyrazinamide probably leads to higher hepatotoxicity compared with isoniazid (moderate certainty).
1 finding from 1 review
Adherence · HIV‐negative people at risk of TB infection1
Rifapentine plus isoniazid weekly probably leads to higher adherence compared with isoniazid daily (moderate certainty).
1 finding from 1 review
Treatment‐limiting adverse events · HIV‐negative people at risk of TB infection1
Rifapentine plus isoniazid weekly probably leads to higher treatment‐limiting adverse events compared with isoniazid daily (moderate certainty).
1 finding from 1 review